Japanese Researchers Discover Potential Liver Cirrhosis Treatment
This article was originally published in PharmAsia News
Liver cirrhosis is caused by certain liver cells secreting collagen. Japan's Sapporo Medical University research team led by Yoshiro Niitsu focuses on a protein that is necessary to produce the collagen and discovered an agent to inhibit the protein. According to Niitsu, treatments on rats have showed that liver fibrosis almost completely resolved with normal liver functions returning. No side effects have been observed. The therapy's animal tests are undergoing, and clinic trails on humans have been planned. The research result has been published by Nature Biotechnology. Currently there are no approved therapies for liver cirrhosis. Niitsu comments that the therapy has a strong therapeutical potential for reversing human liver cirrhosis and also as a regenerative medicine. (Click here for more - Japanese language
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.